At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 378 enrolled
Drug / intervention
Adenosine armdrug
Likely dose
Adenosine arm 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
In Brief
A Phase 3 clinical trial evaluating Adenosine arm for Atrial Fibrillation and Persistent Common Pulmonary Vein. Completed, enrolled 378 participants across 1 site.
Detailed Summary
The investigators studied the effects of adenosine on the reconnection rate after successful pulmonary veins isolation by radiofrequency catheter ablation in patients with drug-resistant atrial fibrillation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedAug 2013
Primary CompletionApr 2015
Study CompletionMay 2015
TodayJul 2026
First PostedAug 30, 2013
Enrollment StartNov 1, 2012
Primary CompletionApr 1, 2015
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.8 years ago
Interventions
Adenosine armdrug
After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.